Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,514.49
(
0.55%
)
US TECH 100
29,158.80
(
1.59%
)
Dow Jones
50,378.61
(
-0.40%
)
Brent Oil
96.69
(
-4.43%
)
Bitcoin
76,003.56
(
-1.64%
)
News Focus
News Focus
Post# of 57984
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

neuroinv

Send PM Follow Ignore
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

neuroinv

Re: Aiming4 post# 4149

Monday, 02/26/2007 4:23:24 PM

Monday, February 26, 2007 4:23:24 PM

Post# of 57984
<<But then again, it was exactly for such an unforeseeable event as the FDA's clinical hold that an in-licensing was first considered>>

That's actually not correct. While the insurance angle was part of it, the initial impetus came from a breadth of pipeline issue--and the possibility of a long delay between a CX717/701 ouitlicensing and the availability of CX1501 for an orphan indication.

NeuroInvestment
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today